| Bioactivity | Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM[1]. | ||||||||||||
| Invitro | Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins[1]. | ||||||||||||
| Name | Mivebresib | ||||||||||||
| CAS | 1445993-26-9 | ||||||||||||
| Formula | C22H19F2N3O4S | ||||||||||||
| Molar Mass | 459.47 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Mivebresib
CAS: 1445993-26-9 F: C22H19F2N3O4S W: 459.47
Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.